Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02895100 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Protagonist Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT02895100 is a Phase 2 study that was terminated before completion, run by Protagonist Therapeutics. The registered enrollment target is 98 participants.
The verdict
NCT02895100, a Phase 2 study, was terminated before completion, sponsored by Protagonist Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
Interventions
- DRUG Placebo
- DRUG PTG-100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02895100
The ClinicalTrials.gov registry entry for NCT02895100 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Protagonist Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02895100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02895100 about?
NCT02895100 is a clinical study titled "Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis". The main objectives of this study are to evaluate the efficacy, safety, and tolerability of daily doses of PTG-100 in subjects with moderate to severe ulcerative colitis (UC).
What is the current status of trial NCT02895100?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2016-12. Estimated completion is 2018-03-26.
What interventions are being tested in trial NCT02895100?
The interventions under investigation include: Placebo (DRUG), PTG-100 (DRUG).
Who is sponsoring clinical trial NCT02895100?
This trial is sponsored by Protagonist Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.